Prelude Therapeutics to Participate in Barclays 27th Annual Global Healthcare Conference

Company Participation - Prelude Therapeutics will participate in the Barclays 27th Annual Global Healthcare Conference on March 11, 2025 [1] - The company's executives, including CEO Kris Vaddi, President and CMO Jane Huang, and CFO Bryant Lim, will engage in a fireside chat at 12:30 p.m. ET [2] Company Overview - Prelude Therapeutics is a clinical-stage precision oncology company focused on developing innovative medicines for cancer patients with high unmet needs [3] - The company's pipeline includes first-in-class SMARCA2 degraders and a potentially best-in-class CDK9 inhibitor, as well as next-generation degrader antibody conjugates [3] - Prelude aims to extend the promise of precision medicine to every cancer patient in need [3]